Delpharm has announced a partnership with the Government of Canada to modernise its injectable drug manufacturing facility in Boucherville. The initiative, backed by a total investment of over CAD 200 million, will enhance production capacity, secure the supply of critical sterile
Delpharm, a Contract Development and Manufacturing Organisation (CDMO), has announced the expansion of its pharmaceutical network with the acquisition of Astellas’ Meppel pharmaceutical manufacturing facility in the Netherlands. The Meppel facility is a fully equipped site spanning 31,600 square meters.
Delpharm Contract Manufacturing & Development (CDMO) Profile Delpharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry, offering a wide range of drug development and manufacturing services. With 18 plants across multiple countries and a turnover
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
